{"id":104653,"date":"2023-09-25T23:45:26","date_gmt":"2023-09-25T23:45:26","guid":{"rendered":"https:\/\/dailytalks.org\/?p=104653"},"modified":"2023-09-25T23:45:26","modified_gmt":"2023-09-25T23:45:26","slug":"bayer-to-present-new-kerendia-finerenone-data-from-comprehensive-clinical-trial-program-across-a-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes","status":"publish","type":"post","link":"https:\/\/dailytalks.org\/?p=104653","title":{"rendered":"Bayer to present new Kerendia&#x2122; (finerenone) data from comprehensive clinical trial program across a broad range of patients with chronic kidney disease and type 2 diabetes"},"content":{"rendered":"<p>Berlin, June 3, 2022, &#8211; Bayer will present new renal and cardiovascular data from the comprehensive Kerendia&#x2122; (finerenone) clinical trial program at the 2022 American Diabetes Association (ADA) 82nd Scientific Sessions. This new data will comprise of further insights from FIDELITY, including late-breaking data from a new post-hoc analysis&#8230;<br \/><a href=\"https:\/\/www.bayer.com\/media\/en-us\/bayer-to-present-new-kerendiatm-finerenone-data-from-comprehensive-clinical-trial-program-across-a-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes\/\" class=\"button purchase\" rel=\"nofollow noopener\" target=\"_blank\">Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Berlin, June 3, 2022, &#8211; Bayer will present new renal and cardiovascular data from the<\/p>\n","protected":false},"author":1,"featured_media":104654,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[41],"tags":[],"class_list":["post-104653","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-americas"],"featured_image_urls":{"full":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/104653-bayer-to-present-new-kerendia-finerenone-data-from-comprehensive-clinical-trial-program-across-a-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes.jpg",1920,1008,false],"thumbnail":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/104653-bayer-to-present-new-kerendia-finerenone-data-from-comprehensive-clinical-trial-program-across-a-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes-150x150.jpg",150,150,true],"medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/104653-bayer-to-present-new-kerendia-finerenone-data-from-comprehensive-clinical-trial-program-across-a-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes-300x158.jpg",300,158,true],"medium_large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/104653-bayer-to-present-new-kerendia-finerenone-data-from-comprehensive-clinical-trial-program-across-a-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes-768x403.jpg",640,336,true],"large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/104653-bayer-to-present-new-kerendia-finerenone-data-from-comprehensive-clinical-trial-program-across-a-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes-1024x538.jpg",640,336,true],"1536x1536":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/104653-bayer-to-present-new-kerendia-finerenone-data-from-comprehensive-clinical-trial-program-across-a-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes-1536x806.jpg",1536,806,true],"2048x2048":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/104653-bayer-to-present-new-kerendia-finerenone-data-from-comprehensive-clinical-trial-program-across-a-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes.jpg",1920,1008,false],"chromenews-featured":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/104653-bayer-to-present-new-kerendia-finerenone-data-from-comprehensive-clinical-trial-program-across-a-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes-1024x538.jpg",1024,538,true],"chromenews-large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/104653-bayer-to-present-new-kerendia-finerenone-data-from-comprehensive-clinical-trial-program-across-a-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes-825x575.jpg",825,575,true],"chromenews-medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/104653-bayer-to-present-new-kerendia-finerenone-data-from-comprehensive-clinical-trial-program-across-a-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes-590x410.jpg",590,410,true]},"author_info":{"display_name":"Jonathan Jeriah","author_link":"https:\/\/dailytalks.org\/?author=1"},"category_info":"<a href=\"https:\/\/dailytalks.org\/?cat=41\" rel=\"category\">Americas<\/a>","tag_info":"Americas","comment_count":"0","_links":{"self":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/104653","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=104653"}],"version-history":[{"count":0,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/104653\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/media\/104654"}],"wp:attachment":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=104653"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=104653"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=104653"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}